share_log

8-K: Current report

SEC announcement ·  Jul 10 03:41
Summary by Futu AI
On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in a clinical trial at Tufts Medical Center for the treatment of Babesiosis using tafenoquine. This trial is significant as it is the first of its kind and aims to confirm the 80% cure rate observed in a previous Yale School of Public Health study. The earlier study, published in Clinical Infectious Diseases, showed promising results in a small group of immunosuppressed patients. While tafenoquine is currently approved for malaria prophylaxis under the name ARAKODA, it is not yet approved for the treatment or prevention of Babesiosis, a tick-borne illness that can be life-threatening, especially in the elderly and immunocompromised. The company's press release, which is...Show More
On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in a clinical trial at Tufts Medical Center for the treatment of Babesiosis using tafenoquine. This trial is significant as it is the first of its kind and aims to confirm the 80% cure rate observed in a previous Yale School of Public Health study. The earlier study, published in Clinical Infectious Diseases, showed promising results in a small group of immunosuppressed patients. While tafenoquine is currently approved for malaria prophylaxis under the name ARAKODA, it is not yet approved for the treatment or prevention of Babesiosis, a tick-borne illness that can be life-threatening, especially in the elderly and immunocompromised. The company's press release, which is part of the SEC filing, outlines the ongoing efforts to repurpose tafenoquine for Babesiosis treatment, with plans to file a New Drug Application with the FDA in the second quarter of 2026. The company is also conducting additional studies to address the unmet medical needs of different Babesiosis patient populations. 60 Degrees Pharmaceuticals, which specializes in infectious disease treatments, has already achieved FDA approval for ARAKODA for malaria prevention and is actively engaged in research collaborations.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.